Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine
Authors
Keywords
-
Journal
DRUGS
Volume 71, Issue 5, Pages 591-602
Publisher
Springer Nature
Online
2011-03-29
DOI
10.2165/11205980-000000000-00000
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old
- (2010) Myron J Levin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Human Papillomavirus-Related Disease in Men: Not Just a Women's Issue
- (2010) Joel M. Palefsky JOURNAL OF ADOLESCENT HEALTH
- Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis
- (2010) Jane J Kim LANCET INFECTIOUS DISEASES
- Clinical Trial and Post-Licensure Safety Profile of a Prophylactic Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine
- (2010) Stan L. Block et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Safety, Tolerability, and Immunogenicity of Gardasil Given Concomitantly With Menactra and Adacel
- (2010) K. S. Reisinger et al. PEDIATRICS
- Seroprevalence and Determinants of Eight High-Risk Human Papillomavirus Types in Homosexual Men, Heterosexual Men, and Women: A Population-Based Study in Amsterdam
- (2010) Marlies Heiligenberg et al. SEXUALLY TRANSMITTED DISEASES
- Post-licensure monitoring of HPV vaccine in the United States
- (2010) Lauri E. Markowitz et al. VACCINE
- Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines
- (2010) A. Arguedas et al. VACCINE
- Impact of vaccinating boys and men against HPV in the United States
- (2010) Elamin H. Elbasha et al. VACCINE
- Postlicensure Safety Surveillance for Quadrivalent Human Papillomavirus Recombinant Vaccine
- (2009) Barbara A. Slade JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Human papillomavirus prevalence and type distribution in penile carcinoma
- (2009) C Miralles-Guri et al. JOURNAL OF CLINICAL PATHOLOGY
- Twenty-Year Trends in the Incidence and Prevalence of Diagnosed Anogenital Warts in Canada
- (2009) Erich V. Kliewer et al. SEXUALLY TRANSMITTED DISEASES
- Cost of Treatment and QALYs Lost Due to Genital Warts: Data for the Economic Evaluation of HPV Vaccines in the United Kingdom
- (2009) Sarah C. Woodhall et al. SEXUALLY TRANSMITTED DISEASES
- Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women
- (2009) C K Fairley et al. SEXUALLY TRANSMITTED INFECTIONS
- Human papillomavirus disease and vaccines
- (2008) D. J. Hutchinson et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Estimation of the incidence of genital warts and the cost of illness in Germany: A cross-sectional study
- (2008) Peter Hillemanns et al. BMC INFECTIOUS DISEASES
- The Case for a Gender-Neutral (Universal) Human Papillomavirus Vaccination Policy in the United States: Point
- (2008) A. R. Giuliano et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- The predicted impact of vaccination on human papillomavirus infections in Australia
- (2008) Megan A. Smith et al. INTERNATIONAL JOURNAL OF CANCER
- Epidemiology of Human Papillomavirus Infection in Men, Cancers other than Cervical and Benign Conditions
- (2008) Anna R. Giuliano et al. VACCINE
- Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines
- (2007) Cosette M. Wheeler et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started